Gilead's (GILD) HCV Drug Application Accepted in the EU

by Zacks Equity Research Published on June 27,2017

Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

• BMY Quick QuoteBMYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change
• GILD Quick QuoteGILDPositive Net Change

Healthcare ETF (IYH) Hits New 52-Week High

by Sweta Killa Published on June 23,2017

This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?

• JNJ Quick QuoteJNJPositive Net Change
• IYH Quick QuoteIYHNegative Net Change
• CLVS Quick QuoteCLVSPositive Net Change

Here's Why Geron (GERN) is a Good Stock to Invest in Now

by Zacks Equity Research Published on June 22,2017

Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.

• JNJ Quick QuoteJNJPositive Net Change
• GERN Quick QuoteGERNNegative Net Change
• REGN Quick QuoteREGNNegative Net Change
• VVUS Quick QuoteVVUSPositive Net Change

Fitch Sees Fastest Global Growth in 10 Years: ETFs To Buy

by Zacks Equity Research Published on June 21,2017

Credit rating agency Fitch expects the global growth to reach 2.9% in 2017 and 3.1% in 2018.

• AMZN Quick QuoteAMZNNegative Net Change
• GOOGL Quick QuoteGOOGLPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• AAPL Quick QuoteAAPLNegative Net Change

Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

by Zacks Equity Research Published on June 21,2017

Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• VVUS Quick QuoteVVUSPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago

by Zacks Equity Research Published on June 21,2017

Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago

• JNJ Quick QuoteJNJPositive Net Change
• NK Quick QuoteNKNo Net Change

J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

by Zacks Equity Research Published on June 20,2017

Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change
• REGN Quick QuoteREGNNegative Net Change

AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?

by Zacks Equity Research Published on June 19,2017

AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.

• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change
• AMGN Quick QuoteAMGNNegative Net Change
• CHRS Quick QuoteCHRSNegative Net Change

Company News for June 19, 2017

by Zacks Equity Research Published on June 19,2017

Companies in the News are: FNSR,JNJ,BHP,DOW,DD

• JNJ Quick QuoteJNJPositive Net Change
• DD Quick QuoteDDNegative Net Change
• DOW Quick QuoteDOWPositive Net Change
• FNSR Quick QuoteFNSRPositive Net Change

J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

by Zacks Equity Research Published on June 19,2017

Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

• RHHBY Quick QuoteRHHBYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• CELG Quick QuoteCELGPositive Net Change

J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

by Zacks Equity Research Published on June 13,2017

Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.

• AZN Quick QuoteAZNPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change

Amgen's Multiple Myeloma Drug Receives NICE Recommendation

by Zacks Equity Research Published on June 13,2017

Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.

• JNJ Quick QuoteJNJPositive Net Change
• VVUS Quick QuoteVVUSPositive Net Change
• CELG Quick QuoteCELGPositive Net Change
• AMGN Quick QuoteAMGNNegative Net Change

J&J Announces EU Regulatory Approval for Actelion Deal

by Zacks Equity Research Published on June 12,2017

Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.

• JNJ Quick QuoteJNJPositive Net Change
• REGN Quick QuoteREGNNegative Net Change
• VVUS Quick QuoteVVUSPositive Net Change
• ALIOF Quick QuoteALIOFNo Net Change

World Bank Foresees 7-Year High Global Growth: ETFs to Buy

by Zacks Equity Research Published on June 07,2017

The World Bank has said that the global economy will grow at 2.9% in 2018, up from 2.7% this year.

• AMZN Quick QuoteAMZNNegative Net Change
• GOOGL Quick QuoteGOOGLPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• AAPL Quick QuoteAAPLNegative Net Change

Microsoft to Add Long-Awaited Features to Outlook on iOS

by Zacks Equity Research Published on June 06,2017

Microsoft Corp. (MSFT) recently announced that it will introduce the option to add and edit contacts from Outlook on Apple's (AAPL) iOS platform.

• JNJ Quick QuoteJNJPositive Net Change
• AAPL Quick QuoteAAPLNegative Net Change
• MSFT Quick QuoteMSFTNegative Net Change

Novartis Biosimilar Pipeline, 2018 Growth Plans on Track

by Zacks Equity Research Published on May 31,2017

Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.

• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change

Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

by Zacks Equity Research Published on May 26,2017

Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• AMGN Quick QuoteAMGNNegative Net Change

Here's Why Alexion Pharma (ALXN) Stock is Sinking Today

by Madeleine Johnson Published on May 23,2017

On Tuesday, shares of Alexion Pharmaceuticals Inc. (ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its executive team.

• NVS Quick QuoteNVSNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change

Dow 30 Stock Roundup: Home Depot, Cisco, Wal-Mart Beat on Earnings

by Swarup Gupta Published on May 19,2017

The Dow traversed another tenuous week, marked by key earnings results and political developments.

• CSCO Quick QuoteCSCOPositive Net Change
• JPM Quick QuoteJPMPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change

Why Is Johnson & Johnson (JNJ) Up 4.4% Since the Last Earnings Report?

by Zacks Equity Research Published on May 19,2017

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• JNJ Quick QuoteJNJPositive Net Change

J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

by Zacks Equity Research Published on May 18,2017

Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• VVUS Quick QuoteVVUSPositive Net Change
• CATB Quick QuoteCATBPositive Net Change

Shares of Colgate-Palmolive (CL) Pop as CEO May Want to Sell

by Madeleine Johnson Published on May 17,2017

On Wednesday, shares of leading global consumer products company Colgate-Palmolive Co. (CL) are popping, up over 5% to $75.25 per share in afternoon trading after the New York Post reported that its CEO, Ian Cook, could be open to a sale.

• JNJ Quick QuoteJNJPositive Net Change
• UL Quick QuoteULNegative Net Change
• KHC Quick QuoteKHCNegative Net Change

AbbVie and J&J Present Positive Imbruvica Leukemia Data

by Zacks Equity Research Published on May 15,2017

AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).

• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change
• VVUS Quick QuoteVVUSPositive Net Change
• GALE Quick QuoteGALENegative Net Change

by Zacks Equity Research Published on May 12,2017

• OUSA Quick QuoteOUSAPositive Net Change
• AAPL Quick QuoteAAPLNegative Net Change
• JNJ Quick QuoteJNJPositive Net Change

Connor O'Brien and Shark Tank's Kevin O'Leary: What are the Keys to Long Term Investing?

by Eric Dutram Published on May 11,2017

The team at O'Sares, which includes Shark Tank's Kevin O'Leary, talks to Eric Dutram about why they jumped into the ETF market, and what they look for when investing for the long term. Check it out in today's podcast!

• JNJ Quick QuoteJNJPositive Net Change
• AAPL Quick QuoteAAPLNegative Net Change
• OASI Quick QuoteOASINo Net Change
• OEUH Quick QuoteOEUHNegative Net Change